Please use this identifier to cite or link to this item:
10.1007/s40123-023-00868-w
Title: | Efficacy and Safety of Quantum Molecular Resonance Electrotherapy in Patients with Aqueous-Deficient, Evaporative and Mixed-Type Dry Eye : A Randomized Interventional Study |
Authors: | Ballesteros-Sánchez, Antonio Sánchez-González, José María Tedesco, Giovanni Roberto Rocha-De-Lossada, Carlos Russo, Fedele Spinelli, Antonio Ingrande, Irene Borroni, Davide Rīga Stradiņš University |
Keywords: | Aqueous-deficient dry eye;Dry eye disease;Evaporative dry eye;Meibomian gland dysfunction;Mixed dry eye;Quantum Molecular Resonance electrotherapy;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Ophthalmology |
Issue Date: | Feb-2024 |
Citation: | Ballesteros-Sánchez , A , Sánchez-González , J M , Tedesco , G R , Rocha-De-Lossada , C , Russo , F , Spinelli , A , Ingrande , I & Borroni , D 2024 , ' Efficacy and Safety of Quantum Molecular Resonance Electrotherapy in Patients with Aqueous-Deficient, Evaporative and Mixed-Type Dry Eye : A Randomized Interventional Study ' , Ophthalmology and Therapy , vol. 13 , no. 2 , pp. 495-507 . https://doi.org/10.1007/s40123-023-00868-w |
Abstract: | Introduction: To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient (ADDE), evaporative (EDE), and mixed (MDE) dry eye. Methods: In this prospective, interventional study, 81 patients were randomly allocated to received four treatment sessions of QMR at 1-week intervals (Rexon-Eye®, Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute four times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo®, Thea Pharma, France) (SH-TH group). Outcome measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM), and meibomian gland dysfunction (MGD) grade, which were assessed at baseline and 1-month and 3-month follow-up. Results: The QMR group achieved better improvements than the SH-TH group in OSDI and SANDE questionnaires, NIBUT, LLT, and CFS. The mean differences between the groups were as follows: OSDI (− 12.4 ± 0.25 points, P = 0.01), SANDE (10.6 ± 1.7 points, P = 0.01), NIBUT (2 ± 0.25 s, P = 0.01), LLT (18.7 ± 0.7 nm, P = 0.01), and CFS (1.2 ± 0.1 points, P = 0.02). In subgroups analysis, QMR treatment demonstrated a beneficial role to improve DED symptoms and signs in ADDE, EDE, and MDE. Conclusion: QMR is an effective and well-tolerated treatment that seems to improve DED symptoms and signs in patients with severe DED. However, further studies are needed to confirm this. Trial Registration: ClinicalTrials.gov identifier NCT06119386. |
Description: | Publisher Copyright: © 2023, The Author(s). |
DOI: | 10.1007/s40123-023-00868-w |
ISSN: | 2193-8245 |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Efficacy_and_Safety_of_Quantum_Molecular_Resonance.pdf | 521.24 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.